These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

218 related articles for article (PubMed ID: 33323970)

  • 21. OCT-4: a novel estrogen receptor-α collaborator that promotes tamoxifen resistance in breast cancer cells.
    Bhatt S; Stender JD; Joshi S; Wu G; Katzenellenbogen BS
    Oncogene; 2016 Nov; 35(44):5722-5734. PubMed ID: 27065334
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Early Enrichment of ESR1 Mutations and the Impact on Gene Expression in Presurgical Primary Breast Cancer Treated with Aromatase Inhibitors.
    Leal MF; Haynes BP; Schuster E; Yeo B; Afentakis M; Zabaglo L; Martins V; Buus R; Dodson A; Cheang MCU; Smith IE; Martin LA; Dowsett M
    Clin Cancer Res; 2019 Dec; 25(24):7485-7496. PubMed ID: 31548345
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The ER-alpha mutation Y537S confers Tamoxifen-resistance via enhanced mitochondrial metabolism, glycolysis and Rho-GDI/PTEN signaling: Implicating TIGAR in somatic resistance to endocrine therapy.
    Fiorillo M; Sanchez-Alvarez R; Sotgia F; Lisanti MP
    Aging (Albany NY); 2018 Dec; 10(12):4000-4023. PubMed ID: 30573703
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Reversal of tamoxifen resistant breast cancer by low dose estrogen therapy.
    Osipo C; Gajdos C; Cheng D; Jordan VC
    J Steroid Biochem Mol Biol; 2005 Feb; 93(2-5):249-56. PubMed ID: 15860267
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Characterization of BCAR4, a novel oncogene causing endocrine resistance in human breast cancer cells.
    Godinho M; Meijer D; Setyono-Han B; Dorssers LC; van Agthoven T
    J Cell Physiol; 2011 Jul; 226(7):1741-9. PubMed ID: 21506106
    [TBL] [Abstract][Full Text] [Related]  

  • 26. CUL4B renders breast cancer cells tamoxifen-resistant via miR-32-5p/ER-α36 axis.
    Wang Y; Pan X; Li Y; Wang R; Yang Y; Jiang B; Sun G; Shao C; Wang M; Gong Y
    J Pathol; 2021 Jun; 254(2):185-198. PubMed ID: 33638154
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Short report: Monitoring ESR1 mutations by circulating tumor DNA in aromatase inhibitor resistant metastatic breast cancer.
    Sefrioui D; Perdrix A; Sarafan-Vasseur N; Dolfus C; Dujon A; Picquenot JM; Delacour J; Cornic M; Bohers E; Leheurteur M; Rigal O; Tennevet I; Thery JC; Alexandru C; Guillemet C; Moldovan C; Veyret C; Frebourg T; Di Fiore F; Clatot F
    Int J Cancer; 2015 Nov; 137(10):2513-9. PubMed ID: 25994408
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Molecular basis for estrogen receptor alpha deficiency in BRCA1-linked breast cancer.
    Hosey AM; Gorski JJ; Murray MM; Quinn JE; Chung WY; Stewart GE; James CR; Farragher SM; Mulligan JM; Scott AN; Dervan PA; Johnston PG; Couch FJ; Daly PA; Kay E; McCann A; Mullan PB; Harkin DP
    J Natl Cancer Inst; 2007 Nov; 99(22):1683-94. PubMed ID: 18000219
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Estrogen receptor-α36 is involved in development of acquired tamoxifen resistance via regulating the growth status switch in breast cancer cells.
    Li G; Zhang J; Jin K; He K; Zheng Y; Xu X; Wang H; Wang H; Li Z; Yu X; Teng X; Cao J; Teng L
    Mol Oncol; 2013 Jun; 7(3):611-24. PubMed ID: 23499324
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Activating
    Toy W; Weir H; Razavi P; Lawson M; Goeppert AU; Mazzola AM; Smith A; Wilson J; Morrow C; Wong WL; De Stanchina E; Carlson KE; Martin TS; Uddin S; Li Z; Fanning S; Katzenellenbogen JA; Greene G; Baselga J; Chandarlapaty S
    Cancer Discov; 2017 Mar; 7(3):277-287. PubMed ID: 27986707
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Selective Androgen Receptor Modulator RAD140 Inhibits the Growth of Androgen/Estrogen Receptor-Positive Breast Cancer Models with a Distinct Mechanism of Action.
    Yu Z; He S; Wang D; Patel HK; Miller CP; Brown JL; Hattersley G; Saeh JC
    Clin Cancer Res; 2017 Dec; 23(24):7608-7620. PubMed ID: 28974548
    [No Abstract]   [Full Text] [Related]  

  • 32. Strategies to degrade estrogen receptor α in primary and ESR1 mutant-expressing metastatic breast cancer.
    Busonero C; Leone S; Bartoloni S; Acconcia F
    Mol Cell Endocrinol; 2019 Jan; 480():107-121. PubMed ID: 30389467
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Wild-type and specific mutant androgen receptor mediates transcription via 17β-estradiol in sex hormone-sensitive cancer cells.
    Susa T; Ikaga R; Kajitani T; Iizuka M; Okinaga H; Tamamori-Adachi M; Okazaki T
    J Cell Physiol; 2015 Jul; 230(7):1594-606. PubMed ID: 25536295
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Development of resistance to targeted therapies transforms the clinically associated molecular profile subtype of breast tumor xenografts.
    Creighton CJ; Massarweh S; Huang S; Tsimelzon A; Hilsenbeck SG; Osborne CK; Shou J; Malorni L; Schiff R
    Cancer Res; 2008 Sep; 68(18):7493-501. PubMed ID: 18794137
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Suppression of breast cancer metastasis and extension of survival by a new antiestrogen in a preclinical model driven by mutant estrogen receptors.
    Laws MJ; Ziegler Y; Shahoei SH; Dey P; Kim SH; Yasuda M; Park BH; Nettles KW; Katzenellenbogen JA; Nelson ER; Katzenellenbogen BS
    Breast Cancer Res Treat; 2020 Jun; 181(2):297-307. PubMed ID: 32277377
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Tamoxifen resistance and metastasis of human breast cancer cells were mediated by the membrane-associated estrogen receptor ER-α36 signaling in vitro.
    Gu W; Dong N; Wang P; Shi C; Yang J; Wang J
    Cell Biol Toxicol; 2017 Apr; 33(2):183-195. PubMed ID: 27837347
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Mutual regulations and breast cancer cell control by steroidogenic enzymes: Dual sex-hormone receptor modulation upon 17β-HSD7 inhibition.
    Sang X; Han H; Li T; Lin SX
    J Steroid Biochem Mol Biol; 2019 Oct; 193():105411. PubMed ID: 31207361
    [TBL] [Abstract][Full Text] [Related]  

  • 38. ESR1 mutation as an emerging clinical biomarker in metastatic hormone receptor-positive breast cancer.
    Brett JO; Spring LM; Bardia A; Wander SA
    Breast Cancer Res; 2021 Aug; 23(1):85. PubMed ID: 34392831
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hotspot ESR1 Mutations Are Multimodal and Contextual Modulators of Breast Cancer Metastasis.
    Li Z; Wu Y; Yates ME; Tasdemir N; Bahreini A; Chen J; Levine KM; Priedigkeit NM; Nasrazadani A; Ali S; Buluwela L; Arnesen S; Gertz J; Richer JK; Troness B; El-Ashry D; Zhang Q; Gerratana L; Zhang Y; Cristofanilli M; Montanez MA; Sundd P; Wallace CT; Watkins SC; Fumagalli C; Guerini-Rocco E; Zhu L; Tseng GC; Wagle N; Carroll JS; Jank P; Denkert C; Karsten MM; Blohmer JU; Park BH; Lucas PC; Atkinson JM; Lee AV; Oesterreich S
    Cancer Res; 2022 Apr; 82(7):1321-1339. PubMed ID: 35078818
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Steroid Hormone Receptor and Infiltrating Immune Cell Status Reveals Therapeutic Vulnerabilities of
    Williams MM; Spoelstra NS; Arnesen S; O'Neill KI; Christenson JL; Reese J; Torkko KC; Goodspeed A; Rosas E; Hanamura T; Sams SB; Li Z; Oesterreich S; Riggins RB; Jacobsen BM; Elias A; Gertz J; Richer JK
    Cancer Res; 2021 Feb; 81(3):732-746. PubMed ID: 33184106
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 11.